GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BMX-001 overview
BMX-001 is under development for the treatment of allergic dermatitis, anal squamous cell carcinoma, rectal adenocarcinoma (RAC), high-grade gliomas, reperfusion injury, squamous cell carcinoma of head and neck cancer including oropharyngeal cancer, laryngeal cancer, hypopharyngeal cancer, oral cavity cancer and metastatic brain tumor. It acts by targeting nuclear factor kappa B (NFkB) and hypoxia-inducible factor 1 alpha (HIF-1 alpha) and is administered by subcutaneous and topical route. BMX-001 is a Mn(III) N-substituted pyridylporphyrin (MnP)-based SOD mimic.
Biomimetix JV overview
Biomimetix JV (Biomimetix) develops a new class of redox active metalloporphyrin compounds for the treatment of inflammatory skin disease and cancer patients undergoing radiation therapy and chemotherapy. Its pipeline products include BMX-001 targeting high-grade glioma, head and neck cancers, brain metastases, and anal cancer and BMX-010 indicated for the treatment of atopic dermatitis, pruritus (itch), acne, psoriasis, rosacea, and other chronic inflammatory skin conditions. Biomimetix’s compounds modulates key nuclear transcription factors to inhibit inflammatory pathways and also stimulating the production of antioxidants. Biomimetix is headquartered in Greenwood Village, Colorado, the US.
For a complete picture of BMX-001’s drug-specific PTSR and LoA scores, buy the report here.
From 
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.